US20110281871A1 - Taar1 ligands - Google Patents

Taar1 ligands Download PDF

Info

Publication number
US20110281871A1
US20110281871A1 US13/190,510 US201113190510A US2011281871A1 US 20110281871 A1 US20110281871 A1 US 20110281871A1 US 201113190510 A US201113190510 A US 201113190510A US 2011281871 A1 US2011281871 A1 US 2011281871A1
Authority
US
United States
Prior art keywords
nicotinamide
piperazin
methyl
phenyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/190,510
Inventor
Guido Galley
Katrin Groebke Zbinden
Roger Norcross
Henri Stalder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/190,510 priority Critical patent/US20110281871A1/en
Publication of US20110281871A1 publication Critical patent/US20110281871A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • biogenic amines The classical biogenic amines (serotonin, norepinephrine, epinephrine, dopamine, histamine) play important roles as neurotransmitters in the central and peripheral nervous system [1]. Their synthesis and storage, as well as their degradation and reuptake after release are tightly regulated. An imbalance in the levels of biogenic amines is known to be responsible for the altered brain function under many pathological conditions [2-5].
  • a second class of endogenous amine compounds, the so-called trace amines (TAs) significantly overlap with the classical biogenic amines regarding structure, metabolism and subcellular localization.
  • the TAs include p-tyramine, ⁇ -phenylethylamine, tryptamine and octopamine, and they are present in the mammalian nervous system at generally lower levels than classical biogenic amines [6].
  • TA-specific receptors had only been hypothesized based on anatomically discrete high-affinity TA binding sites in the CNS of humans and other mammals [10,11]. Accordingly, the pharmacological effects of TAs were believed to be mediated through the well known machinery of classical biogenic amines, by either triggering their release, inhibiting their reuptake or by “cross reacting” with their receptor systems [9,12,13]. This view changed significantly with the recent identification of several members of a novel family of GPCRs, the trace amine associated receptors (TAARs) [7,14]. There are 9 TAAR genes in human (including 3 pseudogenes) and 16 genes in mouse (including 1 pseudogene).
  • TAAR genes do not contain introns (with one exception, TAAR2 contains 1 intron) and are located next to each other on the same chromosomal segment.
  • TAAR1 is in the first subclass of four genes (TAAR1-4) highly conserved between human and rodents. TAs activate TAAR1 via G ⁇ s.
  • Dysregulation of TAs was shown to contribute to the aetiology of various diseases like depression, psychosis, attention deficit hyperactivity disorder, substance abuse, Parkinson's disease, migraine headache, eating disorders, metabolic disorders and therefore TAAR1 ligands have a high potential for the treatment of these diseases.
  • the invention provides a compound of formula
  • the invention includes all racemic mixtures, all their corresponding enantiomers and/or optical isomers.
  • the present invention also provides pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier.
  • the invention further provides methods for the manufacture of the compounds and compositions of the present invention.
  • Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1.
  • the compounds are useful for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
  • ADHD attention deficit hyperactivity disorder
  • psychotic disorders such as schizophrenia
  • neurological diseases such as Parkinson's disease
  • neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension
  • substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
  • the preferred indications using the compounds of the present invention are depression, psychosis, Parkinson's disease, anxiety and attention deficit hyperactivity disorder (ADHD).
  • lower alkyl denotes a saturated straight- or branched-chain group containing from 1 to 7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like.
  • Preferred alkyl groups are groups with 1-4 carbon atoms.
  • lower alkoxy denotes an alkyl group as defined above, which is attached via an oxygen atom.
  • lower alkyl substituted by halogen denotes an alkyl group as defined above, wherein at least one hydrogen atom is replaced by halogen, for example CF 3 , CHF 2 , CH 2 F, CH 2 CF 3 , CH 2 CH 2 CF 3 , CH 2 CF 2 CF 3 and the like.
  • halogen denotes chlorine, iodine, fluorine and bromine.
  • cycloalkyl denotes a saturated carbocyclic ring, containing from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • aryl as used herein is a carbocyclic ring system, containing from 6 to 10 carbon atoms forming one or more rings, and wherein at least one ring is aromatic in nature, for example phenyl, naphthyl or 5,6,7,8-tetrahydronaphthalen-1-yl.
  • the most preferred aryl group is phenyl.
  • heteroaryl as used herein is an aromatic ring system, containing from 5 to 10 ring atoms forming one or more rings, wherein at least one ring atom is a heteroatom selected from the group consisting of O, N and S, and wherein at least one ring is aromatic in nature, for example oxazolyl, pyridyl, thiophenyl, quinolinyl, pyrrolyl, furyl, benzoimidazolyl, imidazolyl and the like.
  • the most preferred group is pyridyl.
  • heterocycloalkyl denotes a fully saturated ring system, wherein one or two ring atoms are N, O or S, for example piperazinyl, pyrrolidinyl, morpholinyl or piperidinyl.
  • “Pharmaceutically acceptable,” such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.
  • pharmaceutically acceptable acid addition salts embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
  • “Therapeutically effective amount” means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
  • Preferred compounds of formula I are those, wherein X is N. Most preferred are compounds of formula
  • Preferred compounds from this group are those, wherein —NR′R′′ together form a heterocycloalkyl group, more specifically 4-methyl-piperazin-1-yl, for example the following compounds
  • Preferred compounds from this group are further those, wherein —NR′R′′ form together a heterocycloalkyl group, for example piperazin-1-yl, such as
  • R 2 is —O-heterocycloalkyl, more specifically 1-methyl-piperidin-4-yloxy, for example the following compound
  • Preferred compounds from this group are those, wherein o is 2 and one of R 2 is NR′R′′ and the other R 2 is halogen, for example the following compounds
  • One embodiment of the invention are compounds of formula I,
  • the compounds of formula I can be prepared in accordance with the process variants as described above and with the following schemes 1 and 2.
  • the starting materials are either commercially available, are otherwise known in the chemical literature, or can be prepared in accordance with methods well known in the art.
  • R 1 , R 2 , W, L, X, n and o are as described above and R′ and R′′ are independently from each other hydrogen, —(CH 2 ) p —O-lower alkyl, —(CH 2 ) p -optionally substituted aryl, —(CH 2 ) p -heteroaryl, —(CH 2 ) p -heterocycloalkyl, or R′ and R′′ together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by lower alkyl, —CH 2 -cycloalkyl, —S(O) 2 CH 3 , —(CH 2 ) p —O-lower alkyl or by substituted aryl, wherein the substitution on aryl is lower alkyl or lower alkoxy and wherein p has the definition as described below.
  • R 1 , R 2 , X, L, W, n and o are as described above and R′′′ is a heterocycloalkyl group, optionally substituted by lower alkyl.
  • R 1 , R 2 , W, L, X, n and o are as described above and R′ and R′′ are independently from each other hydrogen, —(CH 2 ) p —O-lower alkyl, —(CH 2 ) p -optionally substituted aryl, —(CH 2 ) p -heteroaryl, —(CH 2 ) p -heterocycloalkyl, or R′ and R′′ together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by lower alkyl, —CH 2 -cycloalkyl, —S(O) 2 CH 3 , —(CH 2 ) p —O-lower alkyl or by substituted aryl, wherein the substitution on aryl is lower alkyl or lower alkoxy, wherein p has the definition as described below.
  • R 1 , R 2 , W, X, n and o are as described above and R′ and R′′ are independently from each other hydrogen, —(CH 2 ) p —O-lower alkyl, —(CH 2 ) p -optionally substituted aryl, —(CH 2 ) p -heteroaryl, —(CH 2 ) p -heterocycloalkyl, or R′ and R′′ together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by lower alkyl, —CH 2 -cycloalkyl, —S(O) 2 CH 3 , —(CH 2 ) p —O-lower alkyl or by substituted aryl, wherein the substitution on aryl is lower alkyl or lower alkoxy, wherein p has the definition as described below.
  • Amide couplings are carried out in a solvent such as CH 2 Cl 2 , DMF, acetonitrile, THF or mixtures thereof.
  • Activation is effected by an amide coupling reagent such as BOP, BOP-Cl, TBTU, EDCI, EDCI/DMAP and an additive such as HOBT, N-hydroxysuccinimide or N-hydroxy-2-pyridone in the presence of a base like TEA, DIPEA, N-methylmorpholine etc. at 0° C. to 100° C. Reaction times ranged from 1 hr to 72 hrs. Preferred conditions are DMF, BOP and DIPEA at r.t. overnight.
  • Step B Nucleophilic substitution of chloronicotinic acid derivatives by a suitable primary or secondary amine is carried out in a solvent such as DMF in the presence of a base such as TEA, DIPEA, N-methylmorpholine at 50° C. to reflux. Reaction times range from 2 hrs to 72 hrs. Preferred conditions are DMF, DIPEA at 80° C. for 5 hrs.
  • Ester hydrolysis is effected by dissolving it in a suitable solvent like MeOH, EtOH, THF, 1,4-dioxane, water or mixtures thereof and a base like LiOH, NaOH, KOH, Na 2 CO 3 , K 2 CO 3 or Cs 2 CO 3 .
  • a suitable solvent like MeOH, EtOH, THF, 1,4-dioxane, water or mixtures thereof and a base like LiOH, NaOH, KOH, Na 2 CO 3 , K 2 CO 3 or Cs 2 CO 3 .
  • Preferred conditions are NaOH in EtOH/H 2 O.
  • Condition D Nucleophilic substitution of chloronicotinic acid derivatives by a suitable alcohol is carried out in a solvent such as DMSO in the presence of a base such as KOH at 100° C. in the microwave oven. Reaction times range from 5 min to 30 min.
  • Boc cleavage is effected by treatment with a mineral acid such as HCl, HBr, H 2 SO 4 or H 3 PO 4 or a carbonic acid, in a solvent such as CH 2 Cl 2 , dioxane or HOAc at 0 to 60° C.
  • a mineral acid such as HCl, HBr, H 2 SO 4 or H 3 PO 4 or a carbonic acid
  • a solvent such as CH 2 Cl 2 , dioxane or HOAc at 0 to 60° C.
  • Preferred conditions are 4N HCl in dioxane at r.t. overnight.
  • Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography or a combination of these procedures.
  • suitable separation and isolation procedures can be had by reference to the preparations and examples herein below. However, other equivalent separation or isolation procedures could, of course, also be used. Racemic mixtures of chiral compounds of formula I can be separated using chiral HPLC.
  • the compounds of formula I are basic and may be converted to a corresponding acid addition salt.
  • the conversion is accomplished by treatment with at least a stoichiometric amount of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
  • an appropriate acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like
  • organic acids such as acetic acid, propionic acid, glycolic acid,
  • the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent.
  • an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like.
  • the temperature is maintained between 0° C. and 50° C.
  • the resulting salt precipitates spontaneously or may be brought out of solution with a less polar solvent.
  • the acid addition salts of the basic compounds of formula I can be converted to the corresponding free bases by treatment with at least a stoichiometric equivalent of a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.
  • a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.
  • the compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties.
  • compounds of the present invention have a good affinity to the trace amine associated receptors (TAARs), especially TAAR1.
  • TAARs trace amine associated receptors
  • HEK293 cells (ATCC # CRL-1573) were cultured essentially as described Lindemann et al. (2005).
  • HEK293 cells were transfected with the pIRESneo2 expression plasmids containing the TAAR coding sequences (described above) with Lipofectamine 2000 (Invitrogen) according to the instructions of the manufacturer, and 24 hrs post transfection the culture medium was supplemented with 1 mg/ml G418 (Sigma, Buchs, Switzerland).
  • Cells at confluence were rinsed with ice-cold phosphate buffered saline without Ca 2+ and Mg 2+ containing 10 mM EDTA and pelleted by centrifugation at 1000 rpm for 5 min at 4° C. The pellet was then washed twice with ice-cold phosphate buffered saline and cell pellet was frozen immediately by immersion in liquid nitrogen and stored until use at ⁇ 80° C. Cell pellet was then suspended in 20 ml HEPES-NaOH (20 mM), pH 7.4 containing 10 mM EDTA, and homogenized with a Polytron (PT 3000, Kinematica) at 10,000 rpm for 10 s.
  • PT 3000, Kinematica Polytron
  • the homogenate was centrifuged at 48,000 ⁇ g for 30 min at 4° C. and the pellet resuspended in 20 ml HEPES-NaOH (20 mM), pH 7.4 containing 0.1 mM EDTA (buffer A), and homogenized with a Polytron at 10,000 rpm for 10 s. The homogenate was then centrifuged at 48,000 ⁇ g for 30 min at 4° C. and the pellet resuspended in 20 ml buffer A, and homogenized with a Polytron at 10,000 rpm for 10 s. Protein concentration was determined by the method of Pierce (Rockford, Ill.).
  • the homogenate was then centrifuged at 48,000 ⁇ g for 10 min at 4° C., resuspended in HEPES-NaOH (20 mM), pH 7.0 including MgCl 2 (10 mM) and CaCl 2 g protein per ml and (2 mM) (buffer B) at 200 homogenized with a Polytron at 10,000 rpm for 10 s.
  • Binding assay was performed at 4° C. in a final volume of 1 ml, and with an incubation time of 30 min.
  • the radioligand [ 3 H]-rac-2-(1,2,3,4-tetrahydro-1-naphthyl)-2-imidazoline was used at a concentration equal to the calculated K d value of 60 nM to give a bound at around 0.1% of the total added radioligand concentration, and a specific binding which represented approximately 70-80% of the total binding.
  • Non-specific binding was defined as the amount of [ 3 H]-rac-2-(1,2,3,4-tetrahydro-1-naphthyl)-2-imidazoline bound in the presence of the appropriate unlabelled ligand (10 ⁇ M).
  • Competing ligands were tested in a wide range of concentrations (10 pM-30 ⁇ M). The final dimethylsulphoxide concentration in the assay was 2%, and it did not affect radioligand binding. Each experiment was performed in duplicate. All incubations were terminated by rapid filtration through UniFilter-96 plates (Packard Instrument Company) and glass filter GF/C, pre-soaked for at least 2 h in polyethylenimine 0.3%, and using a Filtermate 96 Cell Harvester (Packard Instrument Company). The tubes and filters were then washed 3 times with 1 ml aliquots of cold buffer B. Filters were not dried and soaked in Ultima gold (45 ⁇ l/well, Packard Instrument Company) and bound radioactivity was counted by a TopCount Microplate Scintillation Counter (Packard Instrument Company).
  • the preferred compounds show a Ki value ( ⁇ M) in mouse on TAAR1 in the range of ⁇ 0.1 ⁇ M. Values for representative compounds are shown in the table below.
  • the present invention also provides pharmaceutical compositions containing compounds of the invention, for example compounds of formula (I) and their pharmaceutically acceptable acid addition salts, and a pharmaceutically acceptable carrier.
  • Such pharmaceutical compositions can be in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions or suspensions.
  • the pharmaceutical compositions also can be in the form of suppositories or injectable solutions.
  • the pharmaceutical compounds of the invention in addition to one or more compounds of the invention, contain a pharmaceutically acceptable carrier.
  • Suitable pharmaceutically acceptable carriers include pharmaceutically inert, inorganic and organic carriers. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules.
  • Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually required in the case of soft gelatine capsules.
  • Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like.
  • Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
  • compositions can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • the invention also provides a method for preparing compositions of the invention which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.
  • the most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system, for example the treatment or prevention of depression, psychosis, Parkinson's disease, anxiety and attention deficit hyperactivity disorder (ADHD).
  • disorders of the central nervous system for example the treatment or prevention of depression, psychosis, Parkinson's disease, anxiety and attention deficit hyperactivity disorder (ADHD).
  • ADHD attention deficit hyperactivity disorder
  • the dosage at which compounds of the invention can be administered can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case.
  • the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof.
  • the daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.
  • Tablet Formulation (Wet Granulation) mg/tablet Item Ingredients 5 mg 25 mg 100 mg 500 mg 1. Compound of formula I 5 25 100 500 2. Lactose Anhydrous DTG 125 105 30 150 3. Sta-Rx 1500 6 6 6 30 4. Microcrystalline Cellulose 30 30 30 150 5. Magnesium Stearate 1 1 1 1 Total 167 167 167 831 Manufacturing Procedure 1. Mix items 1, 2, 3 and 4 and granulate with purified water. 2. Dry the granules at 50° C. 3. Pass the granules through suitable milling equipment. 4. Add item 5 and mix for three minutes; compress on a suitable press. Capsule Formulation mg/capsule Item Ingredients 5 mg 25 mg 100 mg 500 mg 1. Compound of formula I 5 25 100 500 2.
  • Methyl 6-chloronicotinate (5.0 g) was dissolved in DMF (75 ml) at r.t. under an argon atmosphere.
  • 1-Methylpiperazine (3.66 ml) and diisopropylethylamine (30.7 ml) were added and the solution was stirred for 5 hours at 80° C.
  • the reaction was quenched with water.
  • the solution was extracted with EtOAc.
  • the water phase was twice washed with EtOAc.
  • the combined organic layers were washed with water and sat. aq. NaCl, dried over MgSO 4 , filtered and concentrated.
  • 6-chloro-nicotinic acid was coupled with 4-phenoxyphenethylamine.
  • the intermediate 6-chloro-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide was reacted with piperidine.
  • 6-chloro-nicotinic acid was coupled with 4-phenoxyphenethylamine.
  • the intermediate 6-chloro-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide was reacted with morpholine.
  • N-phenethyl-6-piperazin-1-yl-nicotinamide was prepared starting from N-Boc-piperazine using phenethylamine in the coupling step. Off-white solid. MS (ISP): 311.4 ([M+H] + )
  • reaction mixture was filtered through a cartridge filled with 2 g SCX/silica gel 1:1, pre-washed with 20 ml methanol and 20 ml dichloromethane, and the reaction product eluted with 20 ml dichloromethane. After evaporation rac-N-[1-(3,4-dichloro-phenyl)-ethyl]-3-fluoro-benzamide was obtained as colorless solid, MS (ISP): 311.9 and 314.0 ((M+H) +. ).
  • N-[2-(3,4-Dichloro-phenyl)-ethyl]-3-fluoro-benzamide was prepared in analogy to Example 40 from 3-fluoro-benzoic acid and 2-(3,4-dichloro-phenyl)-ethylamine: yellow solid,
  • the title compound was prepared in analogy to example 1, but using 2-methoxy-ethylamine in the first step and 2-(4-phenoxy-phenyl)-ethylamine in the third step.
  • the title compound was prepared in analogy to example 1, but using 2-methoxy-ethylamine in the first step and 2-(3-chloro-phenyl)-ethylamine in the third step.
  • the title compound was prepared in analogy to example 1, but using 1-(2-methoxyphenyl)piperazine in the first step and 2-(3-chloro-phenyl)-ethylamine in the third step.
  • the title compound was prepared in analogy to example 1 but using 2-(3-chloro-phenyl)-ethylamine in the first step and 2-pyridin-2-yl-ethylamine in the third step.
  • the title compound was prepared in analogy to example 1, but using 2-(3-chloro-phenyl)-ethylamine in the first step and 2-pyridin-4-yl-ethylamine in the third step.
  • the title compound was prepared in analogy to example 1, but using 2-(aminomethyl)pyridine in the first step and phenethylamine in the third step.
  • the title compound was prepared in analogy to example 1, but starting from 6-phenylamino-nicotinic acid and using 3-phenyl-propylamine in the third step.
  • the title compound was prepared in analogy to example 1, but using 2-(3-chloro-phenyl)-ethylamine in the first step and 3-phenyl-propylamine in the third step.
  • the title compound was prepared in analogy to example 1, but starting from 2-chloro-nicotinic acid methyl ester and subsequently using 3-morpholin-4-yl-propylamine in the first step and phenethylamine in the third step.
  • the title compound was prepared in analogy to example 1, but starting from 2-chloro-nicotinic acid methyl ester and subsequently using 3-morpholin-4-yl-propylamine in the first step and 2-biphenyl-4-yl-ethylamine in the third step.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a compound of formula
Figure US20110281871A1-20111117-C00001
wherein
  • R1, R2, X, L, W, n, and o are defined herein and
  • to pharmaceutically suitable acid addition salts thereof, with the exception of the following compounds
  • 6-(4-methyl-piperazin-1-yl)-N-phenethyl-nicotinamide (CAS 199478-31-4),
  • N-(3,4-dichloro-benzyl)-3-fluoro-benzamide (CAS 424815-98-5),
  • N-(4-chloro-benzyl)-3-fluoro-benzamide (CAS 544661-83-8),
  • N-(3-chloro-benzyl)-3-fluoro-benzamide (CAS 796051-07-5), and
  • N-phenethyl-6-phenylamino-nicotinamide (CAS 571913-74-1).
The compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and are useful for the treatment of CNS disorders.

Description

    PRIORITY TO RELATED APPLICATION(S)
  • This application is a division of U.S. application Ser. No. 12/180,571, filed Jul. 28, 2008, now pending; which claims the benefit of European Application No. 07113752.5, filed Aug. 3, 2007. The entire contents of the above-identified applications are hereby incorporated by reference.
    • BACKGROUND OF THE INVENTION
  • The classical biogenic amines (serotonin, norepinephrine, epinephrine, dopamine, histamine) play important roles as neurotransmitters in the central and peripheral nervous system [1]. Their synthesis and storage, as well as their degradation and reuptake after release are tightly regulated. An imbalance in the levels of biogenic amines is known to be responsible for the altered brain function under many pathological conditions [2-5]. A second class of endogenous amine compounds, the so-called trace amines (TAs) significantly overlap with the classical biogenic amines regarding structure, metabolism and subcellular localization. The TAs include p-tyramine, β-phenylethylamine, tryptamine and octopamine, and they are present in the mammalian nervous system at generally lower levels than classical biogenic amines [6].
  • Their dysregulation has been linked to various psychiatric diseases like schizophrenia and depression [7] and for other conditions like attention deficit hyperactivity disorder, migraine headache, Parkinson's disease, substance abuse and eating disorders [8,9].
  • For a long time, TA-specific receptors had only been hypothesized based on anatomically discrete high-affinity TA binding sites in the CNS of humans and other mammals [10,11]. Accordingly, the pharmacological effects of TAs were believed to be mediated through the well known machinery of classical biogenic amines, by either triggering their release, inhibiting their reuptake or by “cross reacting” with their receptor systems [9,12,13]. This view changed significantly with the recent identification of several members of a novel family of GPCRs, the trace amine associated receptors (TAARs) [7,14]. There are 9 TAAR genes in human (including 3 pseudogenes) and 16 genes in mouse (including 1 pseudogene). The TAAR genes do not contain introns (with one exception, TAAR2 contains 1 intron) and are located next to each other on the same chromosomal segment. The phylogenetic relationship of the receptor genes, in agreement with an in-depth GPCR pharmacophore similarity comparison and pharmacological data suggest that these receptors form three distinct subfamilies [7,14]. TAAR1 is in the first subclass of four genes (TAAR1-4) highly conserved between human and rodents. TAs activate TAAR1 via Gαs. Dysregulation of TAs was shown to contribute to the aetiology of various diseases like depression, psychosis, attention deficit hyperactivity disorder, substance abuse, Parkinson's disease, migraine headache, eating disorders, metabolic disorders and therefore TAAR1 ligands have a high potential for the treatment of these diseases.
  • Therefore, there is a broad interest to increase the knowledge about trace amine associated receptors.
    • REFERENCES USED
    • 1 Deutch, A. Y. and Roth, R. H. (1999) Neurotransmitters. In Fundamental Neuroscience (2nd edn) (Zigmond, M. J., Bloom, F. E., Landis, S. C., Roberts, J. L, and Squire, L. R., eds.), pp. 193-234, Academic Press;
    • 2 Wong, M. L. and Licinio, J. (2001) Research and treatment approaches to depression. Nat. Rev. Neurosci. 2, 343-351;
    • 3 Carlsson, A. et al. (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41, 237-260;
    • 4 Tuite, P. and Riss, J. (2003) Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin. Investig. Drugs 12, 1335-1352,
    • 5 Castellanos, F. X. and Tannock, R. (2002) Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat. Rev. Neurosci. 3, 617-628;
    • 6 Usdin, Earl; Sandler, Merton; Editors. Psychopharmacology Series, Vol. 1: Trace Amines and the Brain. [Proceedings of a Study Group at the 14th Annual Meeting of the American College of Neuropsychoparmacology, San Juan, Puerto Rico] (1976);
    • 7 Lindemann, L. and Hoener, M. (2005) A renaissance in trace amines inspired by a novel GPCR family. Trends in Pharmacol. Sci. 26, 274-281;
    • 8 Branchek, T. A. and Blackburn, T. P. (2003) Trace amine receptors as targets for novel therapeutics: legend, myth and fact. Curr. Op in. Pharmacol. 3, 90-97;
    • 9 Premont, R. T. et al. (2001) Following the trace of elusive amines. Proc. Natl. Acad. Sci. U.S. A. 98, 9474-9475;
    • 10 Mousseau, D. D. and Butterworth, R. F. (1995) A high-affinity [3H] tryptamine binding site in human brain. Prog. Brain Res. 106, 285-291;
    • 11 McCormack, J. K. et al. (1986) Autoradiographic localization of tryptamine binding sites in the rat and dog central nervous system. J. Neurosci. 6, 94-101;
    • 12 Dyck, L. E. (1989) Release of some endogenous trace amines from rat striatal slices in the presence and absence of a monoamine oxidase inhibitor. Life Sci. 44, 1149-1156;
    • 13 Parker, E. M. and Cubeddu, L. X. (1988) Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. J. Pharmacol. Exp. Ther. 245, 199-210;
    • 14 Lindemann, L. et al. (2005) Trace amine associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics 85, 372-385.
    SUMMARY OF THE INVENTION
  • The invention provides a compound of formula
  • Figure US20110281871A1-20111117-C00002
  • wherein
    • R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, —O—(CH2)p-aryl or aryl;
    • R2 is halogen, lower alkyl substituted by halogen, NR′R″, —(CH2)p-heteroaryl or is —O-heterocycloalkyl, wherein the substitution on heteroaryl or heterocycloalkyl is lower alkyl;
    • R′ and R″ are each independently hydrogen, —(CH2)p—O-lower alkyl, —(CH2)p-optionally substituted aryl, —(CH2)p-heteroaryl, —(CH2)p-heterocycloalkyl, or R′ and R″ together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by lower alkyl, —CH2-cycloalkyl,
      • —S(O)2CH3, —(CH2)p—O-lower alkyl or by substituted aryl wherein the substitution on aryl is lower alkyl or lower alkoxy;
    • W is phenyl, benzo[1,3]dioxolyl, pyridine-2,3- or 4-yl, indolyl or cycloalkyl;
    • L is —CH2—, —CH(CH3)—, —CH2CH2—, —CH2CH(CH3)— or —CH2CH2CH2—;
    • X is N or CH;
    • n is 1 or 2; in case n is 2, each R′ can be the same or different;
    • o is 1 or 2; in case o is 2, each R2 can be the same or different; and
    • p is 0, 1, 2 or 3,
      or to a pharmaceutically suitable acid addition salt thereof, with the exception of the following compounds
    • 6-(4-methyl-piperazin-1-yl)-N-phenethyl-nicotinamide (CAS 199478-31-4),
    • N-(3,4-dichloro-benzyl)-3-fluoro-benzamide (CAS 424815-98-5),
    • N-(4-chloro-benzyl)-3-fluoro-benzamide (CAS 544661-83-8),
    • N-(3-chloro-benzyl)-3-fluoro-benzamide (CAS 796051-07-5), and
    • N-phenethyl-6-phenylamino-nicotinamide (CAS 571913-74-1).
  • The invention includes all racemic mixtures, all their corresponding enantiomers and/or optical isomers.
  • The present invention also provides pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier. The invention further provides methods for the manufacture of the compounds and compositions of the present invention.
  • Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1.
  • The compounds are useful for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
  • The preferred indications using the compounds of the present invention are depression, psychosis, Parkinson's disease, anxiety and attention deficit hyperactivity disorder (ADHD).
    • DETAILED DESCRIPTION OF THE INVENTION
  • The following definitions of the general terms used in the present description apply irrespective of whether the terms in question appear alone or in combination. It must be noted that, as used in the specification and the appended claims, the singular forms “a”, “an,” and “the” include plural forms unless the context clearly dictates otherwise.
  • As used herein, the term “lower alkyl” denotes a saturated straight- or branched-chain group containing from 1 to 7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred alkyl groups are groups with 1-4 carbon atoms.
  • As used herein, the term “lower alkoxy” denotes an alkyl group as defined above, which is attached via an oxygen atom.
  • As used herein, the term “lower alkyl substituted by halogen” denotes an alkyl group as defined above, wherein at least one hydrogen atom is replaced by halogen, for example CF3, CHF2, CH2F, CH2CF3, CH2CH2CF3, CH2CF2CF3 and the like.
  • The term “halogen” denotes chlorine, iodine, fluorine and bromine.
  • The term “cycloalkyl” denotes a saturated carbocyclic ring, containing from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • The term “aryl” as used herein is a carbocyclic ring system, containing from 6 to 10 carbon atoms forming one or more rings, and wherein at least one ring is aromatic in nature, for example phenyl, naphthyl or 5,6,7,8-tetrahydronaphthalen-1-yl. The most preferred aryl group is phenyl.
  • The term “heteroaryl” as used herein is an aromatic ring system, containing from 5 to 10 ring atoms forming one or more rings, wherein at least one ring atom is a heteroatom selected from the group consisting of O, N and S, and wherein at least one ring is aromatic in nature, for example oxazolyl, pyridyl, thiophenyl, quinolinyl, pyrrolyl, furyl, benzoimidazolyl, imidazolyl and the like. The most preferred group is pyridyl.
  • The term heterocycloalkyl denotes a fully saturated ring system, wherein one or two ring atoms are N, O or S, for example piperazinyl, pyrrolidinyl, morpholinyl or piperidinyl.
  • “Pharmaceutically acceptable,” such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.
  • The term “pharmaceutically acceptable acid addition salts” embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
  • “Therapeutically effective amount” means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
  • Preferred compounds of formula I are those, wherein X is N. Most preferred are compounds of formula
  • Figure US20110281871A1-20111117-C00003
  • wherein
    • R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, —O—(CH2)p-aryl or aryl;
    • R′ and R″ are each independently hydrogen, —(CH2)p—O-lower alkyl, —(CH2)p-optionally substituted aryl, —(CH2)p-heteroaryl, —(CH2)p-heterocycloalkyl, or R′ and R″ together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by lower alkyl, —CH2-cycloalkyl, —S(O)2CH3, —(CH2)p—O-lower alkyl or by substituted aryl wherein the substitution on aryl is lower alkyl or lower alkoxy
    • W is phenyl, benzo[1,3]dioxolyl, pyridine-2,3- or 4-yl, indolyl or cycloalkyl;
    • L is —CH2—, —CH(CH3)—, —CH2CH2—, —CH2CH(CH3)—, —CH2CH2CH2—,
    • n is 1 or 2; in case n is 2, each IV can be the same or different;
    • p is 0, 1, 2 or 3;
      or a pharmaceutically suitable acid addition salt thereof, with the exception of the following compounds
    • 6-(4-methyl-piperazin-1-yl)-N-phenethyl-nicotinamide (CAS 199478-31-4) and
    • N-phenethyl-6-phenylamino-nicotinamide (CAS 571913-74-1).
  • Preferred compounds from this group are those, wherein —NR′R″ together form a heterocycloalkyl group, more specifically 4-methyl-piperazin-1-yl, for example the following compounds
    • N-benzyl-6-(4-methyl-piperazin-1-yl)-nicotinamide,
    • (N-(4-chloro-benzyl)-6-(4-methyl-piperazin-1-yl)-nicotinamide,
    • N-[2-(4-chloro-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide,
    • N-[2-(3-chloro-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide,
    • 6-(4-methyl-piperazin-1-yl)-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-nicotinamide,
    • N-[2-(4-methoxy-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide,
    • N-[2-(3-methoxy-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide,
    • N-(2-benzo[1,3]dioxol-5-yl-ethyl)-6-(4-methyl-piperazin-1-yl)-nicotinamide,
    • N-(2-biphenyl-4-yl-ethyl)-6-(4-methyl-piperazin-1-yl)-nicotinamide,
    • 6-(4-methyl-piperazin-1-yl)-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide,
    • 6-(4-methyl-piperazin-1-yl)-N-[2-(3-phenoxy-phenyl)-ethyl]-nicotinamide,
    • N-[2-(4-benzyloxy-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide,
    • N-[2-(1-methyl-1H-indol-3-yl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide,
    • N-(2-cyclohexyl-ethyl)-6-(4-methyl-piperazin-1-yl)-nicotinamide, or
    • N-cyclohexylmethyl-6-(4-methyl-piperazin-1-yl)-nicotinamide.
  • Preferred compounds from this group are further those, wherein —NR′R″ form together a heterocycloalkyl group, for example piperazin-1-yl, such as
    • N-[2-(4-chloro-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide,
    • N-[2-(4-phenoxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide,
    • N-[2-(3-phenoxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide, or
    • N-[2-(4-benzyloxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide.
  • Further preferred are compounds, wherein R2 is —O-heterocycloalkyl, more specifically 1-methyl-piperidin-4-yloxy, for example the following compound
    • 6-(1-Methyl-piperidin-4-yloxy)-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide.
  • Preferred compounds from this group are those, wherein o is 2 and one of R2 is NR′R″ and the other R2 is halogen, for example the following compounds
    • 5-bromo-N-[2-(4-chloro-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide,
    • 5-bromo-6-(4-methyl-piperazin-1-yl)-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide,
    • 5-bromo-N-[2-(4-chloro-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide, or
    • 5-bromo-N-[2-(4-phenoxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide.
  • One embodiment of the invention are compounds of formula I,
  • Figure US20110281871A1-20111117-C00004
  • wherein
    • R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, —O—(CH2)p-aryl or aryl;
    • R2 is halogen, lower alkyl substituted by halogen, NR′R″, —(CH2)p-heteroaryl or —O-heterocycloalkyl, wherein the substitution on heteroaryl or heterocycloalkyl is lower alkyl;
    • R′ and R″ are each independently hydrogen, —(CH2)p—O-lower alkyl, —(CH2)p-optionally substituted aryl, —(CH2)p-heteroaryl, —(CH2)p-heterocycloalkyl, or R′ and R″ together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by lower alkyl, —CH2-cycloalkyl, —S(O)2CH3, —(CH2)p—O-lower alkyl or by substituted aryl wherein the substitution on aryl is lower alkyl or lower alkoxy;
    • Ar is phenyl, benzo[1,3]dioxolyl, pyridine-2,3- or 4-yl or is indolyl;
    • L is —CH2—, —CH(CH3)—, —CH2CH2—, —CH2CH(CH3)— or —CH2CH2CH2—;
    • X is N or CH;
    • n is 1 or 2; in case n is 2, each R′ can be the same or different;
    • o is 1 or 2; in case o is 2, each R2 can be the same or different;
    • p is 0, 1, 2 or 3;
      or a pharmaceutically suitable acid addition salt thereof, with the exception of the following compounds
    • 6-(4-methyl-piperazin-1-yl)-N-phenethyl-nicotinamide,
    • N-(3,4-dichloro-benzyl)-3-fluoro-benzamide,
    • N-(4-chloro-benzyl)-3-fluoro-benzamide,
    • N-(3-chloro-benzyl)-3-fluoro-benzamide, and
    • N-phenethyl-6-phenylamino-nicotinamide.
  • The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by processes described below, which processes comprise
  • a) reacting a compound of formula
  • Figure US20110281871A1-20111117-C00005
  • with an amine of formula
  • Figure US20110281871A1-20111117-C00006
  • to give a compound of formula
  • Figure US20110281871A1-20111117-C00007
  • wherein the definitions are as described above, or
  • if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.
  • The compounds of formula I can be prepared in accordance with the process variants as described above and with the following schemes 1 and 2. The starting materials are either commercially available, are otherwise known in the chemical literature, or can be prepared in accordance with methods well known in the art.
    • General Procedure
  • Figure US20110281871A1-20111117-C00008
  • The definition of substituents is as described above.
  • Figure US20110281871A1-20111117-C00009
  • The definitions of R1, R2, W, L, X, n and o are as described above and R′ and R″ are independently from each other hydrogen, —(CH2)p—O-lower alkyl, —(CH2)p-optionally substituted aryl, —(CH2)p-heteroaryl, —(CH2)p-heterocycloalkyl, or R′ and R″ together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by lower alkyl, —CH2-cycloalkyl, —S(O)2CH3, —(CH2)p—O-lower alkyl or by substituted aryl, wherein the substitution on aryl is lower alkyl or lower alkoxy and wherein p has the definition as described below.
  • Figure US20110281871A1-20111117-C00010
  • The definitions of R1, R2, X, L, W, n and o are as described above and R′″ is a heterocycloalkyl group, optionally substituted by lower alkyl.
  • Figure US20110281871A1-20111117-C00011
  • The definitions of R1, R2, W, L, X, n and o are as described above and R′ and R″ are independently from each other hydrogen, —(CH2)p—O-lower alkyl, —(CH2)p-optionally substituted aryl, —(CH2)p-heteroaryl, —(CH2)p-heterocycloalkyl, or R′ and R″ together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by lower alkyl, —CH2-cycloalkyl, —S(O)2CH3, —(CH2)p—O-lower alkyl or by substituted aryl, wherein the substitution on aryl is lower alkyl or lower alkoxy, wherein p has the definition as described below.
  • Figure US20110281871A1-20111117-C00012
  • The definitions of R1, R2, W, X, n and o are as described above and R′ and R″ are independently from each other hydrogen, —(CH2)p—O-lower alkyl, —(CH2)p-optionally substituted aryl, —(CH2)p-heteroaryl, —(CH2)p-heterocycloalkyl, or R′ and R″ together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by lower alkyl, —CH2-cycloalkyl, —S(O)2CH3, —(CH2)p—O-lower alkyl or by substituted aryl, wherein the substitution on aryl is lower alkyl or lower alkoxy, wherein p has the definition as described below.
  • Condition A: Amide couplings are carried out in a solvent such as CH2Cl2, DMF, acetonitrile, THF or mixtures thereof. Activation is effected by an amide coupling reagent such as BOP, BOP-Cl, TBTU, EDCI, EDCI/DMAP and an additive such as HOBT, N-hydroxysuccinimide or N-hydroxy-2-pyridone in the presence of a base like TEA, DIPEA, N-methylmorpholine etc. at 0° C. to 100° C. Reaction times ranged from 1 hr to 72 hrs. Preferred conditions are DMF, BOP and DIPEA at r.t. overnight.
  • Step B: Nucleophilic substitution of chloronicotinic acid derivatives by a suitable primary or secondary amine is carried out in a solvent such as DMF in the presence of a base such as TEA, DIPEA, N-methylmorpholine at 50° C. to reflux. Reaction times range from 2 hrs to 72 hrs. Preferred conditions are DMF, DIPEA at 80° C. for 5 hrs.
  • Condition C: Ester hydrolysis is effected by dissolving it in a suitable solvent like MeOH, EtOH, THF, 1,4-dioxane, water or mixtures thereof and a base like LiOH, NaOH, KOH, Na2CO3, K2CO3 or Cs2CO3.
  • Preferred conditions are NaOH in EtOH/H2O.
  • Condition D: Nucleophilic substitution of chloronicotinic acid derivatives by a suitable alcohol is carried out in a solvent such as DMSO in the presence of a base such as KOH at 100° C. in the microwave oven. Reaction times range from 5 min to 30 min.
  • Condition E: Boc cleavage is effected by treatment with a mineral acid such as HCl, HBr, H2SO4 or H3PO4 or a carbonic acid, in a solvent such as CH2Cl2, dioxane or HOAc at 0 to 60° C. Preferred conditions are 4N HCl in dioxane at r.t. overnight.
  • The following abbreviations have been used:
    • DMF=N,N-dimethylformamide
    • BOP=benzotriazol-1-yloxy-tri(dimethyl-amino)phosphonium hexafluorophosphate
    • EDCI=1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
    • DMAP=4-dimethylaminopyridine
    • HOBT=1-hydroxybenzotriazole hydrate
    • THF=tetrahydrofurane
    • DMSO=methyl sulfoxide
    Isolation and Purification of the Compounds
  • Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the preparations and examples herein below. However, other equivalent separation or isolation procedures could, of course, also be used. Racemic mixtures of chiral compounds of formula I can be separated using chiral HPLC.
    • Salts of Compounds of Formula I
  • The compounds of formula I are basic and may be converted to a corresponding acid addition salt. The conversion is accomplished by treatment with at least a stoichiometric amount of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Typically, the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent. The temperature is maintained between 0° C. and 50° C. The resulting salt precipitates spontaneously or may be brought out of solution with a less polar solvent.
  • The acid addition salts of the basic compounds of formula I can be converted to the corresponding free bases by treatment with at least a stoichiometric equivalent of a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.
  • The compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, compounds of the present invention have a good affinity to the trace amine associated receptors (TAARs), especially TAAR1.
  • The compounds were investigated in accordance with the test given hereinafter.
    • Materials and Methods Construction of TAAR Expression Plasmids and Stably Transfected Cell Lines
  • For the construction of expression plasmids the coding sequences of human, rat and mouse TAAR 1 were amplified from genomic DNA essentially as described by Lindemann et al. [14]. The Expand High Fidelity PCR System (Roche Diagnostics) was used with 1.5 mM Mg2 and purified PCR products were cloned into pCR2.1-TOPO cloning vector (Invitrogen) following the instructions of the manufacturer. PCR products were subcloned into the pIRESneo2 vector (BD Clontech, Palo Alto, Calif.), and expression vectors were sequence verified before introduction in cell lines.
  • HEK293 cells (ATCC # CRL-1573) were cultured essentially as described Lindemann et al. (2005). For the generation of stably transfected cell lines HEK293 cells were transfected with the pIRESneo2 expression plasmids containing the TAAR coding sequences (described above) with Lipofectamine 2000 (Invitrogen) according to the instructions of the manufacturer, and 24 hrs post transfection the culture medium was supplemented with 1 mg/ml G418 (Sigma, Buchs, Switzerland). After a culture period of about 10 d clones were isolated, expanded and tested for responsiveness to trace amines (all compounds purchased from Sigma) with the cAMP Biotrak Enzyme immunoassay (EIA) System (Amersham) following the non-acetylation EIA procedure provided by the manufacturer. Monoclonal cell lines which displayed a stable EC50 for a culture period of 15 passages were used for all subsequent studies.
    • Membrane Preparation and Radioligand Binding
  • Cells at confluence were rinsed with ice-cold phosphate buffered saline without Ca2+ and Mg2+ containing 10 mM EDTA and pelleted by centrifugation at 1000 rpm for 5 min at 4° C. The pellet was then washed twice with ice-cold phosphate buffered saline and cell pellet was frozen immediately by immersion in liquid nitrogen and stored until use at −80° C. Cell pellet was then suspended in 20 ml HEPES-NaOH (20 mM), pH 7.4 containing 10 mM EDTA, and homogenized with a Polytron (PT 3000, Kinematica) at 10,000 rpm for 10 s. The homogenate was centrifuged at 48,000×g for 30 min at 4° C. and the pellet resuspended in 20 ml HEPES-NaOH (20 mM), pH 7.4 containing 0.1 mM EDTA (buffer A), and homogenized with a Polytron at 10,000 rpm for 10 s. The homogenate was then centrifuged at 48,000×g for 30 min at 4° C. and the pellet resuspended in 20 ml buffer A, and homogenized with a Polytron at 10,000 rpm for 10 s. Protein concentration was determined by the method of Pierce (Rockford, Ill.). The homogenate was then centrifuged at 48,000×g for 10 min at 4° C., resuspended in HEPES-NaOH (20 mM), pH 7.0 including MgCl2 (10 mM) and CaCl2 g protein per ml and (2 mM) (buffer B) at 200 homogenized with a Polytron at 10,000 rpm for 10 s.
  • Binding assay was performed at 4° C. in a final volume of 1 ml, and with an incubation time of 30 min. The radioligand [3H]-rac-2-(1,2,3,4-tetrahydro-1-naphthyl)-2-imidazoline was used at a concentration equal to the calculated Kd value of 60 nM to give a bound at around 0.1% of the total added radioligand concentration, and a specific binding which represented approximately 70-80% of the total binding. Non-specific binding was defined as the amount of [3H]-rac-2-(1,2,3,4-tetrahydro-1-naphthyl)-2-imidazoline bound in the presence of the appropriate unlabelled ligand (10 μM). Competing ligands were tested in a wide range of concentrations (10 pM-30 μM). The final dimethylsulphoxide concentration in the assay was 2%, and it did not affect radioligand binding. Each experiment was performed in duplicate. All incubations were terminated by rapid filtration through UniFilter-96 plates (Packard Instrument Company) and glass filter GF/C, pre-soaked for at least 2 h in polyethylenimine 0.3%, and using a Filtermate 96 Cell Harvester (Packard Instrument Company). The tubes and filters were then washed 3 times with 1 ml aliquots of cold buffer B. Filters were not dried and soaked in Ultima gold (45 μl/well, Packard Instrument Company) and bound radioactivity was counted by a TopCount Microplate Scintillation Counter (Packard Instrument Company).
  • The preferred compounds show a Ki value (μM) in mouse on TAAR1 in the range of <0.1 μM. Values for representative compounds are shown in the table below.
  • Ki (μM) Ki (μM) Ki (μM)
    Example mouse Example mouse Example mouse
    1 0.071 13 0.004 31 0.006
    2 0.013 14 0.068 32 0.005
    6 0.005 15 0.006 33 0.019
    7 0.027 18 0.023 34 0.009
    8 0.010 24 0.019 54 0.012
    9 0.091 26 0.081 55 0.062
    10 0.049 28 0.016 A 0.044
    11 0.043 29 0.071
    12 0.028 30 0.028
  • The present invention also provides pharmaceutical compositions containing compounds of the invention, for example compounds of formula (I) and their pharmaceutically acceptable acid addition salts, and a pharmaceutically acceptable carrier. Such pharmaceutical compositions can be in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions or suspensions. The pharmaceutical compositions also can be in the form of suppositories or injectable solutions.
  • The pharmaceutical compounds of the invention, in addition to one or more compounds of the invention, contain a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers include pharmaceutically inert, inorganic and organic carriers. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
  • The pharmaceutical compositions can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • The invention also provides a method for preparing compositions of the invention which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.
  • The most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system, for example the treatment or prevention of depression, psychosis, Parkinson's disease, anxiety and attention deficit hyperactivity disorder (ADHD).
  • The dosage at which compounds of the invention can be administered can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.
  • Tablet Formulation (Wet Granulation)
    mg/tablet
    Item Ingredients 5 mg 25 mg 100 mg 500 mg
    1. Compound of formula I 5 25 100 500
    2. Lactose Anhydrous DTG 125 105 30 150
    3. Sta-Rx 1500 6 6 6 30
    4. Microcrystalline Cellulose 30 30 30 150
    5. Magnesium Stearate 1 1 1 1
    Total 167 167 167 831
    Manufacturing Procedure
    1. Mix items 1, 2, 3 and 4 and granulate with purified water.
    2. Dry the granules at 50° C.
    3. Pass the granules through suitable milling equipment.
    4. Add item 5 and mix for three minutes; compress on a suitable press.
    Capsule Formulation
    mg/capsule
    Item Ingredients 5 mg 25 mg 100 mg 500 mg
    1. Compound of formula I 5 25 100 500
    2. Hydrous Lactose 159 123 148 —
    3. Corn Starch 25 35 40 70
    4. Talc 10 15 10 25
    5. Magnesium Stearate 1 2 2 5
    Total 200 200 300 600
    Manufacturing Procedure
    1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.
    2. Add items 4 and 5 and mix for 3 minutes.
    3. Fill into a suitable capsule.
    • EXPERIMENTAL
  • The following examples illustrate the invention but are not intended to limit its scope.
    • Example 1 N-Benzyl-6-(4-methyl-piperazin-1-yl)-nicotinamide a) 6-(4-Methyl-piperazin-1-yl)-nicotinic acid methyl ester
  • Figure US20110281871A1-20111117-C00013
  • Methyl 6-chloronicotinate (5.0 g) was dissolved in DMF (75 ml) at r.t. under an argon atmosphere. 1-Methylpiperazine (3.66 ml) and diisopropylethylamine (30.7 ml) were added and the solution was stirred for 5 hours at 80° C. The reaction was quenched with water. The solution was extracted with EtOAc. The water phase was twice washed with EtOAc. The combined organic layers were washed with water and sat. aq. NaCl, dried over MgSO4, filtered and concentrated. The crude product was purified by column chromatography (silica gel; gradient: CH2Cl2->CH2Cl2/MeOH 9:1) to give 6-(4-methyl-piperazin-1-yl)-nicotinic acid methyl ester (5.59 g) as light yellow solid.
  • MS (ISP): 236.1 ([M+H]+).
    • b) 6-(4-Methyl-piperazin-1-yl)-nicotinic acid
  • Figure US20110281871A1-20111117-C00014
  • A solution of 6-(4-methyl-piperazin-1-yl)-nicotinic acid methyl ester (5.56 g) in MeOH/H2O 1:1 (100 ml) was cooled to 0° C. and treated with NaOH (1.9 g). The reaction mixture was stirred for 45 min at 0° C. and for 5 hrs at r.t., then neutralized with 1N HCl and concentrated. The crude product was used in the next reaction step without further purification.
  • MS (ISP): 220.6 ([M−H])
    • c) N-Benzyl-6-(4-methyl-piperazin-1-yl)-nicotinamide
  • Figure US20110281871A1-20111117-C00015
  • A suspension of 6-(4-methyl-piperazin-1-yl)-nicotinic acid (200 mg) in DMF (2 ml) was treated under an argon atmosphere with diisopropylamine (0.50 ml), benzylamine (0.12 ml) and BOP (600 mg). The reaction mixture was stirred at r.t. overnight, then diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over MgSO4, filtered and concentrated. The crude product was purified by column chromatography (silica gel; gradient: CH2Cl2->CH2Cl2/MeOH 9:1) to give N-benzyl-6-(4-methyl-piperazin-1-yl)-nicotinamide (120 mg) as off-white solid. MS (ISP): 311.3 ([M+H]+)
  • In analogy to example 1c using the appropriate amine component were prepared:
    • Example 2 (N-(4-Chloro-benzyl)-6-(4-methyl-piperazin-1-yl)-nicotinamide
  • Figure US20110281871A1-20111117-C00016
  • Amine: 4-chlorobenzylamine. Off-white solid. MS (ISP): 345.1 ([M+H]+ 9
    • Example 3 6-(4-Methyl-piperazin-1-yl)-N-(4-phenoxy-benzyl)-nicotinamide
  • Figure US20110281871A1-20111117-C00017
  • Amine: 4-phenoxybenzylamine. White solid. MS (ISP): 403.5 ([M+H]+])
    • Example 4 N-Benzyl-6-piperazin-1-yl-nicotinamide a) 4-(5-Benzylcarbamoyl-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester
  • Figure US20110281871A1-20111117-C00018
  • In analogy to example 1 4-(5-phenethylcarbamoyl-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester was prepared starting from N-Boc-piperazine and using benzylamine in the last coupling step. Light yellow solid. MS (ISP): 397.5 ([M+H]+)
    • b) N-Benzyl-6-piperazin-1-yl-nicotinamide
  • Figure US20110281871A1-20111117-C00019
  • A solution of 4-(5-phenethylcarbamoyl-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester (200 mg) in MeOH (5 ml) was cooled to 0° C. and slowly treated with 4N HCl (2.52 ml). The reaction mixture was stirred at r.t. overnight, then diluted with CH2Cl2 and directly purified by column chromatography (Isolute® SPE flash NH2 column, aminopropyl-functionalized silica; gradient: CH2Cl2->CH2Cl2/MeOH 9:1) to give N-benzyl-6-piperazin-1-yl-nicotinamide as off-white solid. MS (ISP): 297.5 ([M+H]+)
  • In analogy to example 1c using the appropriate amine component were prepared:
    • Example 5 (RS)-6-(4-Methyl-piperazin-1-yl)-N-(2-phenyl-propyl)-nicotinamide
  • Figure US20110281871A1-20111117-C00020
  • Amine: 2-methylphenylethylamine. White solid. MS (ISP): 339.3 ([M+H]+)
    • Example 6 N-[2-(4-Chloro-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide
  • Figure US20110281871A1-20111117-C00021
  • Amine: 2-(4-chlorophenyl)ethylamine. White solid. MS (ISP): 359.1 ([M+H]+)
    • Example 7 N-[2-(3-Chloro-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide
  • Figure US20110281871A1-20111117-C00022
  • Amine: 2-(3-chlorophenyl)ethylamine. White solid. MS (ISP): 359.1 ([M+H]+)
    • Example 8 6-(4-Methyl-piperazin-1-yl)-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-nicotinamide
  • Figure US20110281871A1-20111117-C00023
  • Amine: 2-(3-trifluoromethylphenyl)ethylamine. White solid. MS (ISP): 393.3 ([M+H]+)
    • Example 9 N-[2-(4-Methoxy-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide
  • Figure US20110281871A1-20111117-C00024
  • Amine: 2-(4-methoxyphenyl)ethylamine. Off-white solid. MS (ISP): 355.4 ([M+H]+)
    • Example 10 N-[2-(3-Methoxy-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide
  • Figure US20110281871A1-20111117-C00025
  • Amine: 2-(3-methoxyphenyl)ethylamine. Colorless oil. MS (ISP): 355.4 ([M+H]+)
    • Example 11 N-(2-Benzo[1,3]dioxol-5-yl-ethyl)-6-(4-methyl-piperazin-1-yl)-nicotinamide
  • Figure US20110281871A1-20111117-C00026
  • Amine: 3,4-methylenedioxyphenethylamine hydrochloride. White solid. MS (ISP): 369.4 ([M+H]+)
    • Example 12 N-(2-Biphenyl-4-yl-ethyl)-6-(4-methyl-piperazin-1-yl)-nicotinamide
  • Figure US20110281871A1-20111117-C00027
  • Amine: 2-(4-biphenyl)ethylamine. White solid. MS (ISP): 401.5 ([M+H]+)
    • Example 13 6-(4-Methyl-piperazin-1-yl)-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide
  • Figure US20110281871A1-20111117-C00028
  • Amine: 4-phenoxyphenetylamine. Off-white solid. MS (ISP): 417.4 ([M+H]+)
    • Example 14 6-(4-Methyl-piperazin-1-yl)-N-[2-(3-phenoxy-phenyl)-ethyl]-nicotinamide
  • Figure US20110281871A1-20111117-C00029
  • Amine: 3-phenoxyphenethylamine. Off-white solid. MS (ISP): 417.4 ([M+H]+)
    • Example 15 N-[2-(4-Benzyloxy-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide
  • Figure US20110281871A1-20111117-C00030
  • Amine: 2-(4-benzyloxy-phenyl)-ethylamine. Off-white solid. MS (ISP): 431.5 ([M+H]+)
    • Example 16 6-(4-Methyl-piperazin-1-yl)-N-(2-pyridin-2-yl-ethyl)-nicotinamide
  • Figure US20110281871A1-20111117-C00031
  • Amine: 2-(2-aminoethyl)pyridine. Light yellow solid. MS (ISP): 326.5 ([M+H]+)
    • Example 17 6-(4-Methyl-piperazin-1-yl)-N-(2-pyridin-3-yl-ethyl)-nicotinamide
  • Figure US20110281871A1-20111117-C00032
  • Amine: 3-(2-aminoethyl)pyridine. Light yellow solid. MS (ISP): 326.3 ([M+H]+)
    • Example 18 N-[2-(1-Methyl-1H-indol-3-yl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide
  • Figure US20110281871A1-20111117-C00033
  • Amine: 1-methyltryptamine. Off-white liquid. MS (ISP): 378.4 ([M+H]+)
    • Example 19 N-[2-(1H-Indol-3-yl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide
  • Figure US20110281871A1-20111117-C00034
  • Amine: tryptamine. Off-white solid. MS (ISP): 364.3 ([M+H]+)
    • Example 20 N-[2-(4-Chloro-phenyl)-ethyl]-6-(4-cyclopropylmethyl-piperazin-1-yl)-nicotinamide a) 6-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-nicotinamide
  • Figure US20110281871A1-20111117-C00035
  • In analogy to example 1.c 6-chloro-nicotinic acid was coupled with 2-(4-chlorophenyl)ethylamine. Light yellow solid. MS (ISP): 294.0 ([M+H]+)
    • b) N-[2-(4-Chloro-phenyl)-ethyl]-6-(4-cyclopropylmethyl-piperazin-1-yl)-nicotinamide
  • Figure US20110281871A1-20111117-C00036
  • In analogy to example 1.a 6-chloro-N-[2-(4-chloro-phenyl)-ethyl]-nicotinamide was reacted with 1-(cyclopropylmethyl)piperazine. Off-white solid. MS (ISP): 399.3 ([M+H]+)
    • Example 21 N-[2-(4-Chloro-phenyl)-ethyl]-6-[4-(2-methoxy-ethyl)-piperazin-1-yl]-nicotinamide
  • Figure US20110281871A1-20111117-C00037
  • In analogy to example 21.b 6-chloro-N-[2-(4-chloro-phenyl)-ethyl]-nicotinamide was reacted with 1-(2-methoxyethyl)piperazine. Light yellow solid. MS (ISP): 403.3 ([M+H]+)
    • Example 22 N-[2-(4-Phenoxy-phenyl)-ethyl]-6-pyrrolidin-1-yl-nicotinamide
  • Figure US20110281871A1-20111117-C00038
  • In analogy to example 21, 6-chloro-nicotinic acid was coupled with 4-phenoxyphenethylamine. The intermediate 6-chloro-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide was reacted with piperidine. White solid. MS (ISP): 388.3 ([M+H]+)
    • Example 23 6-Morpholin-4-yl-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide
  • Figure US20110281871A1-20111117-C00039
  • In analogy to example 21 6-chloro-nicotinic acid was coupled with 4-phenoxyphenethylamine. The intermediate 6-chloro-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide was reacted with morpholine. White solid. MS (ISP): 404.6 ([M+H]+])
    • Example 24 6-(1-Methyl-piperidin-4-yloxy)-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide
  • Figure US20110281871A1-20111117-C00040
  • A solution of 6-chloro-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide (130 mg, intermediate from example 23) in DMSO (1.4 ml) was treated with 4-hydroxy-N-methylpiperidine (68 mg) and KOH (93 mg). The reaction mixture was heated for 20 min at 100° C. in the microwave oven. Then it was cooled to r.t. and diluted with CH2Cl2 and water. The aqueous layer was washed with CH2Cl2. The combined organic layers were dried over MgSO4, filtered and concentrated. The crude product was purified by column chromatography (silica gel; gradient: CH2Cl2->CH2Cl2/MeOH 98:2) to give 6-(1-methyl-piperidin-4-yloxy)-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide (29 mg) as off-white solid. MS (ISP): 432.2 ([M+H]+)
    • Example 25 N-Phenethyl-6-piperazin-1-yl-nicotinamide
  • Figure US20110281871A1-20111117-C00041
  • In analogy to example 4 N-phenethyl-6-piperazin-1-yl-nicotinamide was prepared starting from N-Boc-piperazine using phenethylamine in the coupling step. Off-white solid. MS (ISP): 311.4 ([M+H]+)
  • In analogy to example 26 and using the appropriate amine in the coupling step the following derivatives were prepared:
    • Example 26 N-[2-(4-Chloro-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide
  • Figure US20110281871A1-20111117-C00042
  • Amine: 2-(4-chlorophenyl)ethylamine. Off-white solid. MS (ISP): 345.1 ([M+H]+)
    • Example 27 N-[2-(3-Chloro-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide
  • Figure US20110281871A1-20111117-C00043
  • Amine: 2-(3-chlorophenyl)ethylamine. Amorphous colorless solid. MS (ISP): 345.0 ([M+H]+)
    • Example 28 N-[2-(4-Phenoxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide
  • Figure US20110281871A1-20111117-C00044
  • Amine: 4-phenoxyphenethylamine. Off-white solid. MS (ISP): 403.5 ([M+H]+)
    • Example 29 N-[2-(3-Phenoxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide
  • Figure US20110281871A1-20111117-C00045
  • Amine: 3-phenoxyphenethylamine. Light yellow amorphous solid. MS (ISP): 403.5 ([M+H]+)
    • Example 30 N-[2-(4-Benzyloxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide
  • Figure US20110281871A1-20111117-C00046
  • Amine: 2-(4-benzyloxy-phenyl)-ethylamine. Off-white solid. MS (ISP): 417.4 ([M+H]+)
    • Example 31 5-Bromo-N-[2-(4-chloro-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide
  • Figure US20110281871A1-20111117-C00047
  • In analogy to example 1, 5-bromo-6-chloro-nicotinic acid methyl ester was reacted with N-methylpiperazine and then, using 4-chlorophenethylamine in the coupling step, converted to 5-bromo-N-[2-(4-chloro-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide. Off-white solid. MS (ISP): 437.0 ([M+H]+)
    • Example 32 5-Bromo-6-(4-methyl-piperazin-1-yl)-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide
  • Figure US20110281871A1-20111117-C00048
  • In analogy to example 32 and using 4-phenoxyphenethylamine in the coupling step 5-bromo-6-chloro-nicotinic acid methyl ester was converted to 5-bromo-6-(4-methyl-piperazin-1-yl)-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide. Off-white solid.
  • MS (ISP): 495.1 ([M+H]+)
    • Example 33 5-Bromo-N-[2-(4-chloro-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide
  • Figure US20110281871A1-20111117-C00049
  • In analogy to example 26 5-bromo-6-chloro-nicotinic acid methyl ester reacted with N-Boc-piperazine and then, using 4-chlorophenethylamine in the coupling step, converted to 5-bromo-N-[2-(4-chloro-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide. Off-white solid. MS (ISP): 423.1 ([M+H]+)
    • Example 34 5-Bromo-N-[2-(4-phenoxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide
  • Figure US20110281871A1-20111117-C00050
  • In analogy to example 26, 5-bromo-6-chloro-nicotinic acid methyl ester reacted with N-Boc-piperazine and then, using 4-phenoxyphenethylamine in the coupling step, converted to 5-bromo-N-[2-(4-phenoxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide. Off-white solid. MS (ISP): 481.0 ([M+H]+)
    • Example 35 N-[2-(4-Chloro-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-4-trifluoromethyl-nicotinamide
  • Figure US20110281871A1-20111117-C00051
  • In analogy to example 1 methyl 6-chloro-4-(trifluoromethyl)nicotinate was reacted with N-methylpiperazine and then, using 4-chlorophenethylamine in the coupling step, converted to N-[2-(4-chloro-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-4-trifluoro-methyl-nicotinamide. Off-white solid. MS (ISP): 427.2 ([M+H]+)
    • Example 36 6-(4-Methyl-piperazin-1-yl)-N-[2-(4-phenoxy-phenyl)-ethyl]-4-trifluoromethyl-nicotinamide
  • Figure US20110281871A1-20111117-C00052
  • In analogy to example 1 methyl 6-chloro-4-(trifluoromethyl)nicotinate was reacted with N-methylpiperazine and then, using 4-phenoxyphenethylamine in the coupling step, converted to 6-(4-methyl-piperazin-1-yl)-N-[2-(4-phenoxy-phenyl)-ethyl]-4-trifluoro-methyl-nicotinamide. Off-white solid. MS (ISP): 485.2 ([M+H]+)
    • Example 37 2-Chloro-6-(4-methyl-piperazin-1-yl)-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide
  • Figure US20110281871A1-20111117-C00053
  • In analogy to example 21 methyl 2,6-dichloronicotinic acid was coupled with 4-phenoxyphenethylamine and then reacted with N-methylpiperazine. Yellow solid.
  • MS (ISP): 451.0 ([M+H]+)
    • Example 38 2-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide a) 4-{6-Chloro-5-[2-(4-chloro-phenyl)-ethylcarbamoyl]-pyridin-2-yl}-piperazine-1-carbo-xylic acid tert-butyl ester
  • Figure US20110281871A1-20111117-C00054
  • In analogy to example 38 methyl 2,6-dichloronicotinic acid was coupled with 4-chlorophenethylamine and then reacted with N-Boc-piperazine. Light yellow solid.
  • MS (ISP): 479.0 ([M+H]+)
    • b) 2-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide
  • Figure US20110281871A1-20111117-C00055
  • In analogy to example 4.b 4-[6-chloro-5-[2-(4-chloro-phenyl)-ethylcarbamoyl]-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester was converted to 2-chloro-N-[2-(4-chloro-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide. Light yellow solid.
  • MS (ISP): 379.2 ([M+H]+)
    • Example 39 2-Chloro-N-[2-(4-phenoxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide a) 4-{6-Chloro-5-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-pyridin-2-yl}-piperazine-1-carboxylic acid tert-butyl ester
  • Figure US20110281871A1-20111117-C00056
  • In analogy to example 38 methyl 2,6-dichloronicotinic acid was coupled with 4-phenoxyphenethylamine and then reacted with N-Boc-piperazine. Yellow solid.
  • MS (ISP): 537.0 ([M+H]+)
    • b) 2-Chloro-N-[2-(4-phenoxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide
  • Figure US20110281871A1-20111117-C00057
  • In analogy to example 4.b 4-{6-chloro-5-[2-(4-phenoxy-phenyl)-ethylcarbamoyl]-pyridin-2-yl}-piperazine-1-carboxylic acid tert-butyl ester was converted to 2-chloro-N-[2-(4-phenoxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide. Off-white solid.
  • MS (ISP): 437.1 ([M+H]+).
    • Example 40 rac-N-[1-(3,4-Dichloro-phenyl)-ethyl]-3-fluoro-benzamide
  • Figure US20110281871A1-20111117-C00058
  • To a solution of 143.8 mg (0.75 mmol) N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC.HCl) and 91.6 mg (0.75 mmol) 4-dimethylaminopyridine (DMAP) in 1.5 ml dichloromethane were added 142 mg (0.75 mmol) rac-1-(3,4-dichloro-phenyl)-ethylamine and the solution stirred at ambient temperature for 5 min. To this solution were added 70 mg (0.5 mmol) 3-fluoro-benzoic acid and the mixture stirred at ambient temperature for 5 hours.
  • The reaction mixture was filtered through a cartridge filled with 2 g SCX/silica gel 1:1, pre-washed with 20 ml methanol and 20 ml dichloromethane, and the reaction product eluted with 20 ml dichloromethane. After evaporation rac-N-[1-(3,4-dichloro-phenyl)-ethyl]-3-fluoro-benzamide was obtained as colorless solid, MS (ISP): 311.9 and 314.0 ((M+H)+.).
    • Example 41 N-[2-(3,4-Dichloro-phenyl)-ethyl]-3-fluoro-benzamide
  • Figure US20110281871A1-20111117-C00059
  • N-[2-(3,4-Dichloro-phenyl)-ethyl]-3-fluoro-benzamide was prepared in analogy to Example 40 from 3-fluoro-benzoic acid and 2-(3,4-dichloro-phenyl)-ethylamine: yellow solid,
  • MS (ISP): 311.9 and 314.0 ((M+H)+.).
    • Example 42 6-(2-Methoxy-ethylamino)-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide
  • Figure US20110281871A1-20111117-C00060
  • The title compound was prepared in analogy to example 1, but using 2-methoxy-ethylamine in the first step and 2-(4-phenoxy-phenyl)-ethylamine in the third step.
  • MS (ISP): 392.2 ((M+H)+.).
    • Example 43 N-[2-(3-Chloro-phenyl)-ethyl]-6-(2-methoxy-ethylamino)-nicotinamide
  • Figure US20110281871A1-20111117-C00061
  • The title compound was prepared in analogy to example 1, but using 2-methoxy-ethylamine in the first step and 2-(3-chloro-phenyl)-ethylamine in the third step.
    • Example 44 N-[2-(3-Chloro-phenyl)-ethyl]-6-[4-(2-methoxy-phenyl)-piperazin-1-yl]-nicotinamide
  • Figure US20110281871A1-20111117-C00062
  • The title compound was prepared in analogy to example 1, but using 1-(2-methoxyphenyl)piperazine in the first step and 2-(3-chloro-phenyl)-ethylamine in the third step.
    • Example 45 6-[2-(3-Chloro-phenyl)-ethylamino]-N-(2-pyridin-2-yl-ethyl)-nicotinamide
  • Figure US20110281871A1-20111117-C00063
  • The title compound was prepared in analogy to example 1 but using 2-(3-chloro-phenyl)-ethylamine in the first step and 2-pyridin-2-yl-ethylamine in the third step.
    • Example 46 6-[2-(3-Chloro-phenyl)-ethylamino]-N-(2-pyridin-4-yl-ethyl)-nicotinamide
  • Figure US20110281871A1-20111117-C00064
  • The title compound was prepared in analogy to example 1, but using 2-(3-chloro-phenyl)-ethylamine in the first step and 2-pyridin-4-yl-ethylamine in the third step.
    • Example 47 N-Phenethyl-6-[(pyridin-2-ylmethyl)-amino]-nicotinamide
  • Figure US20110281871A1-20111117-C00065
  • The title compound was prepared in analogy to example 1, but using 2-(aminomethyl)pyridine in the first step and phenethylamine in the third step.
  • MS (ISP): 333.2 ((M+H)+.).
    • Example 48 6-Phenylamino-N-(3-phenyl-propyl)-nicotinamide
  • Figure US20110281871A1-20111117-C00066
  • The title compound was prepared in analogy to example 1, but starting from 6-phenylamino-nicotinic acid and using 3-phenyl-propylamine in the third step.
    • Example 49 6-[2-(3-Chloro-phenyl)-ethylamino]-N-(3-phenyl-propyl)-nicotinamide
  • Figure US20110281871A1-20111117-C00067
  • The title compound was prepared in analogy to example 1, but using 2-(3-chloro-phenyl)-ethylamine in the first step and 3-phenyl-propylamine in the third step.
    • Example 50 2-(3-Morpholin-4-yl-propylamino)-N-phenethyl-nicotinamide
  • Figure US20110281871A1-20111117-C00068
  • The title compound was prepared in analogy to example 1, but starting from 2-chloro-nicotinic acid methyl ester and subsequently using 3-morpholin-4-yl-propylamine in the first step and phenethylamine in the third step.
    • Example 51 2-(4-Methanesulfonyl-piperazin-1-yl)-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide
  • Figure US20110281871A1-20111117-C00069
  • The title compound was prepared in analogy to example 1, but starting from 2-chloro-nicotinic acid methyl ester and subsequently using 1-methanesulfonyl-piperazine in the first step and 2-(4-phenoxy-phenyl)-ethylamine in the third step. MS (ISP): 481.1 ((M+H)+.).
    • Example 52 N-(2-Biphenyl-4-yl-ethyl)-2-(3-morpholin-4-yl-propylamino)-nicotinamide
  • Figure US20110281871A1-20111117-C00070
  • The title compound was prepared in analogy to example 1, but starting from 2-chloro-nicotinic acid methyl ester and subsequently using 3-morpholin-4-yl-propylamine in the first step and 2-biphenyl-4-yl-ethylamine in the third step.
    • Example 53 N-[2-(2-Fluoro-phenyl)-ethyl]-4-(2-methyl-benzoimidazol-1-ylmethyl)-benzamide
  • Figure US20110281871A1-20111117-C00071
  • The title compound was prepared in analogy to example 1c, but using 2-(2-fluoro-phenyl)-ethylamine and 4-(2-methyl-benzoimidazol-1-ylmethyl)-benzoic acid as coupling components. MS (ISP): 388.2 ((M+H)+.).
    • Example 54 N-(2-Cyclohexyl-ethyl)-6-(4-methyl-piperazin-1-yl)-nicotinamide
  • Figure US20110281871A1-20111117-C00072
  • The title compound was prepared in analogy to example 1c, but using 2-cyclohexyl-ethylamine as amine component in the coupling reaction. Off-white solid. MS (ISP): 331.4 ((M+H)+.).
    • Example 55 N-Cyclohexylmethyl-6-(4-methyl-piperazin-1-yl)-nicotinamide
  • Figure US20110281871A1-20111117-C00073
  • The title compound was prepared in analogy to example 1c, but using cyclohexyl-methylamine as amine component in the coupling reaction. Off-white solid. MS (ISP): 317.3 ((M+H)+.).
    • Examples A-E
  • Additionally the following known compounds were prepared as TAAR1 ligands using procedures analogous to those describe above:
    • A: 6-(4-methyl-piperazin-1-yl)-N-phenethyl-nicotinamide (CAS 199478-31-4)
    • B: N-(3,4-dichloro-benzyl)-3-fluoro-benzamide (CAS 424815-98-5)
    • C: N-(4-chloro-benzyl)-3-fluoro-benzamide (CAS 544661-83-8)
    • D: N-(3-chloro-benzyl)-3-fluoro-benzamide (CAS 796051-07-5)
    • E: N-phenethyl-6-phenylamino-nicotinamide (CAS 571913-74-1).

Claims (15)

1. A compound of formula
Figure US20110281871A1-20111117-C00074
wherein
R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, —O—(CH2)p-aryl or aryl;
R2 is halogen, lower alkyl substituted by halogen, NR′R″, —(CH2)p-heteroaryl or is —O-heterocycloalkyl, wherein the substitution on heteroaryl or heterocycloalkyl is lower alkyl;
R′ and R″ are each independently hydrogen, —(CH2)p—O-lower alkyl, —(CH2)p-optionally substituted aryl, —(CH2)p-heteroaryl, —(CH2)p-heterocycloalkyl, or R′ and R″ together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by lower alkyl, —CH2-cycloalkyl, —S(O)2CH3, —(CH2)p—O-lower alkyl or by substituted aryl wherein the substitution on aryl is lower alkyl or lower alkoxy;
W is phenyl, benzo[1,3]dioxolyl, pyridine-2,3- or 4-yl, indolyl or cycloalkyl;
L is —CH2—, —CH(CH3)—, —CH2CH2—, —CH2CH(CH3)— or —CH2CH2CH2—;
X is N or CH;
n is 1 or 2; in case n is 2, each R1 can be the same or different;
o is 1 or 2; in case o is 2, each R2 can be the same or different; and
p is 0, 1, 2 or 3;
or a pharmaceutically suitable acid addition salt thereof, with the exception of the following compounds
6-(4-methyl-piperazin-1-yl)-N-phenethyl-nicotinamide,
N-(3,4-dichloro-benzyl)-3-fluoro-benzamide,
N-(4-chloro-benzyl)-3-fluoro-benzamide,
N-(3-chloro-benzyl)-3-fluoro-benzamide, and
N-phenethyl-6-phenylamino-nicotinamide.
2. A compound of claim 1 wherein X is N.
3. A compound of claim 1 having formula IA
Figure US20110281871A1-20111117-C00075
wherein
R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, —O—(CH2)p-aryl or aryl;
R′ and R″ are each independently hydrogen, —(CH2)p—O-lower alkyl, —(CH2)p-optionally substituted aryl, —(CH2)p-heteroaryl, —(CH2)p-heterocycloalkyl, or R′ and R″ together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by lower alkyl, —CH2-cycloalkyl, —S(O)2CH3, —(CH2)p—O-lower alkyl or by substituted aryl wherein the substitution on aryl is lower alkyl or lower alkoxy
W is phenyl, benzo[1,3]dioxolyl, pyridine-2,3- or 4-yl, indolyl or cycloalkyl;
L is —CH2—, —CH(CH3)—, —CH2CH2—, —CH2CH(CH3)—, —CH2CH2CH2—,
n is 1 or 2; in case n is 2, R′ may be the same or different;
p is 0, 1, 2 or 3,
or a pharmaceutically suitable acid addition salt thereof, with the exception of the following compounds
6-(4-methyl-piperazin-1-yl)-N-phenethyl-nicotinamide and
N-phenethyl-6-phenylamino-nicotinamide.
4. A compound of claim 2, wherein R′ and R″ together with the N atom to which they are attached form a heterocycloalkyl group.
5. A compound of claim 4, wherein the heterocyclic group is
4-methyl-piperazin-1-yl.
6. A compound of claim 5, selected from the group consisting of
N-benzyl-6-(4-methyl-piperazin-1-yl)-nicotinamide,
(N-(4-chloro-benzyl)-6-(4-methyl-piperazin-1-yl)-nicotinamide,
N-[2-(4-chloro-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide,
N-[2-(3-chloro-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide,
6-(4-methyl-piperazin-1-yl)-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-nicotinamide,
N-[2-(4-methoxy-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide,
N-[2-(3-methoxy-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide,
N-(2-benzo[1,3]dioxol-5-yl-ethyl)-6-(4-methyl-piperazin-1-yl)-nicotinamide,
N-(2-biphenyl-4-yl-ethyl)-6-(4-methyl-piperazin-1-yl)-nicotinamide,
6-(4-methyl-piperazin-1-yl)-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide,
6-(4-methyl-piperazin-1-yl)-N-[2-(3-phenoxy-phenyl)-ethyl]-nicotinamide,
N-[2-(4-benzyloxy-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide,
N-[2-(1-methyl-1H-indol-3-yl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide,
N-(2-cyclohexyl-ethyl)-6-(4-methyl-piperazin-1-yl)-nicotinamide, and
N-cyclohexyl-methyl-6-(4-methyl-piperazin-1-yl)-nicotinamide.
7. A compound of claim 4, wherein the heterocycloalkyl group is piperazin-1-yl.
8. A compound of claim 7, selected from the group consisting of
N-[2-(4-chloro-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide,
N-[2-(4-phenoxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide,
N-[2-(3-phenoxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide, and
N-[2-(4-benzyloxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide.
9. A compound of claim 1, wherein R2 is —O-heterocycloalkyl.
10. A compound of claim 9, wherein the O-heterocycloalkyl group is 1-methyl-piperidin-4-yloxy.
11. A compound of claim 10, wherein the compound is 6-(1-methyl-piperidin-4-yloxy)-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide.
12. A compound of claim 1, wherein o is 2 and one of R2 is NR′R″ and the other R2 is halogen.
13. A compound of claim 12, selected from the group consisting of
5-bromo-N-[2-(4-chloro-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-nicotinamide,
5-bromo-6-(4-methyl-piperazin-1-yl)-N-[2-(4-phenoxy-phenyl)-ethyl]-nicotinamide,
5-bromo-N-[2-(4-chloro-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide, and
5-bromo-N-[2-(4-phenoxy-phenyl)-ethyl]-6-piperazin-1-yl-nicotinamide.
14. A compound of claim 1, wherein W is Ar.
15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
Figure US20110281871A1-20111117-C00076
wherein
R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, —O—(CH2)p-aryl or aryl;
R2 is halogen, lower alkyl substituted by halogen, NR′R″, —(CH2)p-heteroaryl or is —O-heterocycloalkyl, wherein the substitution on heteroaryl or heterocycloalkyl is lower alkyl;
R′ and R″ are each independently hydrogen, —(CH2)p—O-lower alkyl, —(CH2)p-optionally substituted aryl, —(CH2)p-heteroaryl, —(CH2)p-heterocycloalkyl, or R′ and R″ together with the N atom to which they are attached form a heterocycloalkyl group optionally substituted by lower alkyl, —CH2-cycloalkyl, —S(O)2CH3, —(CH2)p—O-lower alkyl or by substituted aryl wherein the substitution on aryl is lower alkyl or lower alkoxy;
W is phenyl, benzo[1,3]dioxolyl, pyridine-2,3- or 4-yl, indolyl or cycloalkyl;
L is —CH2—, —CH(CH3)—, —CH2CH2—, —CH2CH(CH3)— or —CH2CH2CH2—;
X is N or CH;
n is 1 or 2; in case n is 2, each R1 can be the same or different;
o is 1 or 2; in case o is 2, each R2 can be the same or different; and
p is 0, 1, 2 or 3;
or a pharmaceutically suitable acid addition salt thereof, with the exception of the following compounds
6-(4-methyl-piperazin-1-yl)-N-phenethyl-nicotinamide,
N-(3,4-dichloro-benzyl)-3-fluoro-benzamide,
N-(4-chloro-benzyl)-3-fluoro-benzamide,
N-(3-chloro-benzyl)-3-fluoro-benzamide, and
N-phenethyl-6-phenylamino-nicotinamide
and a pharmaceutically acceptable carrier.
US13/190,510 2007-08-03 2011-07-26 Taar1 ligands Abandoned US20110281871A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/190,510 US20110281871A1 (en) 2007-08-03 2011-07-26 Taar1 ligands

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07113752 2007-08-03
EP07113752.5 2007-08-03
US12/180,571 US8008305B2 (en) 2007-08-03 2008-07-28 TAAR1 ligands
US13/190,510 US20110281871A1 (en) 2007-08-03 2011-07-26 Taar1 ligands

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/180,571 Division US8008305B2 (en) 2007-08-03 2008-07-28 TAAR1 ligands

Publications (1)

Publication Number Publication Date
US20110281871A1 true US20110281871A1 (en) 2011-11-17

Family

ID=39811481

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/180,571 Expired - Fee Related US8008305B2 (en) 2007-08-03 2008-07-28 TAAR1 ligands
US13/190,510 Abandoned US20110281871A1 (en) 2007-08-03 2011-07-26 Taar1 ligands

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/180,571 Expired - Fee Related US8008305B2 (en) 2007-08-03 2008-07-28 TAAR1 ligands

Country Status (13)

Country Link
US (2) US8008305B2 (en)
EP (1) EP2185502A1 (en)
JP (1) JP5341084B2 (en)
KR (1) KR101167773B1 (en)
CN (1) CN101784515A (en)
AR (1) AR067772A1 (en)
AU (1) AU2008285795A1 (en)
BR (1) BRPI0814758A2 (en)
CA (1) CA2695331A1 (en)
CL (1) CL2008002268A1 (en)
PE (1) PE20090896A1 (en)
TW (1) TW200914021A (en)
WO (1) WO2009019149A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2587437C (en) * 2004-11-22 2015-01-13 Thomson Licensing Methods, apparatus and system for film grain cache splitting for film grain simulation
EP2350010B1 (en) 2008-10-30 2014-03-26 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
TWI504395B (en) 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TWI475020B (en) * 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI461197B (en) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
EP2608672B1 (en) * 2010-08-23 2020-12-16 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
WO2012025236A1 (en) 2010-08-27 2012-03-01 Grünenthal GmbH Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators
AU2011295408B2 (en) 2010-08-27 2015-05-14 Grünenthal GmbH Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators
AU2011295406B2 (en) 2010-08-27 2015-08-06 Grunenthal Gmbh Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators
EP2611780A1 (en) 2010-09-01 2013-07-10 Grünenthal GmbH Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators
ES2554843T3 (en) * 2012-01-12 2015-12-23 F. Hoffmann-La Roche Ag Heterocyclic derivatives as associated amine trace receptors (TAARs)
WO2014152229A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
HUE039262T2 (en) * 2014-05-28 2018-12-28 Hoffmann La Roche 5-oxa-2-azabicyclo[2.2.2]octan-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives as taar1 modulators
CN104478798B (en) * 2014-12-18 2017-01-18 武汉华纳联合药业有限公司 N-aminoalkyl-3-pyridinecarboxamide derivative and application of N-aminoalkyl-3-pyridinecarboxamide derivative in preparation of drugs for treating cardiovascular and cerebrovascular diseases
AU2017234042B2 (en) 2016-03-17 2020-11-19 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of TAAR
CN114426494B (en) * 2022-01-13 2023-09-15 江苏海洋大学 Substituted methylamine derivatives acting on TAAR agonist

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2731471A (en) * 1956-01-17 Nxg hi
FR6551E (en) 1905-07-27 1906-12-17 Carlo Chiesa Rotary drum dryer, removable and transportable, and operating in the open, for cocoons, cereals, etc.
US2161938A (en) * 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
US2457047A (en) * 1946-02-13 1948-12-21 Monsanto Chemicals 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same
US2778836A (en) * 1954-04-02 1957-01-22 Union Chimique Belge Sa Substituted 2-methyl-delta2 imidazolines
US2744909A (en) * 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-phenylbenzyl) imidazoline and acid addition salts
US2744910A (en) * 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts
US2919274A (en) * 1957-09-17 1959-12-29 Sahyun Melville Amidines
GB877306A (en) 1958-04-21 1961-09-13 Pfizer & Co C Halogenated derivatives of tetrahydro-1-naphthyl cyclic amidines
DE1121054B (en) * 1960-11-23 1962-01-04 Merck Ag E Process for the preparation of a new imidazoline derivative and its acid addition salts
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
DE1150180B (en) * 1962-04-12 1963-06-12 Merck Ag E Preparations for pre-treating the skin for shaving
US3459763A (en) 1966-01-25 1969-08-05 Geigy Chem Corp Certain amino imidazole derivatives
ES323985A1 (en) 1966-02-26 1966-12-16 Blade Pique Juan Procedure for obtaining imidazole derivatives. (Machine-translation by Google Translate, not legally binding)
FI48082C (en) * 1966-08-05 1974-06-10 Boehringer Sohn Ingelheim Process for the preparation of antihypertensive 2-arylhydrazinoimidazoline- (2)
US3377247A (en) * 1967-04-28 1968-04-09 Dow Chemical Co Antidepressant method
US3586695A (en) * 1968-01-26 1971-06-22 Dow Chemical Co Substituted imidazolinyl indoles
BE754820R (en) * 1969-08-13 1971-02-15 Schering Ag NEW PYRIMIDINE DERIVATIVES, THEIR METHODS OF PREPARATION AND THEIR
US3622579A (en) * 1969-08-28 1971-11-23 Boehringer Sohn Ingelheim Derivatives of 2-anilino-1,3-diazacyclopentene-(2)
US3818094A (en) * 1969-08-28 1974-06-18 Boehringer Sohn Ingelheim Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2)
US3660423A (en) * 1970-02-13 1972-05-02 Dow Chemical Co 2-(substituted benzyl)methyl-2-imidazolines
GB1333471A (en) * 1971-01-27 1973-10-10 Labaz Imidazoline derivatives and process for preparing the same
US4125620A (en) * 1974-10-01 1978-11-14 Boehringer Ingelheim Gmbh 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof
US3992403A (en) * 1975-05-30 1976-11-16 Schering Corporation 2-Imidazolines and their use as hypoglycemic agents
GB1538097A (en) * 1976-01-26 1979-01-10 Lafon Labor Substituted phenyl-amidines
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
AU518569B2 (en) 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
DE3133887A1 (en) 1981-08-27 1983-03-10 Bayer Ag, 5090 Leverkusen 2-ARYLHYDRAZINO-2-IMIDAZOLINE, THE ACYL DERIVATIVES THEREOF, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR COMBATING ENDO AND EECTOPARASITES
ES518818A0 (en) 1982-01-27 1984-06-16 Pfizer A PROCEDURE FOR THE PREPARATION OF AN ECTOPARASITICIDE, ESPECIALLY ACARICIDE, OR ANTIHELMINTIC COMPOSITION.
US4540705A (en) 1983-03-14 1985-09-10 Sterling Drug Inc. Antidepressant imidazolines and related compounds
EP0166937B1 (en) 1984-06-06 1991-08-28 Abbott Laboratories Adrenergic compounds
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
US4665095A (en) * 1985-12-11 1987-05-12 Abbott Laboratories Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion
GB2215206B (en) 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
FI894911A0 (en) 1989-10-17 1989-10-17 Farmos Oy EN TERAPEUTISKT VAERDEFULL FOERENING.
DE69534283T2 (en) 1993-10-13 2006-03-16 Horacek, H. Joseph CLONIC-CONTAINING MEDICINAL PRODUCT WITH DELAYED ACTIVE INGREDIENTS
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
US5610174A (en) 1995-06-02 1997-03-11 Synaptic Pharmaceutical Corporation Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
TW438796B (en) * 1996-05-15 2001-06-07 Hoffmann La Roche 2,4-diaminopyrimidine derivatives, the manufacture process thereof, and the antibiotically-active pharmaceutical composition containing the same
US5969137A (en) 1996-09-19 1999-10-19 Virginia Commonwealth University Benzylamidine derivatives with serotonin receptor binding activity
IL123232A0 (en) 1997-02-11 1999-11-30 Lilly Co Eli Medicament for inhibiting glucose metabolism deterioration
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
CN1284066A (en) 1997-12-04 2001-02-14 阿勒根销售公司 Substituted inidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors
DK0924209T3 (en) 1997-12-19 2003-08-25 Lilly Co Eli Hypoglycemic imidazoline compounds
CA2328973A1 (en) * 1998-04-23 1999-10-28 Akio Ojida Naphthalene derivatives, their production and use
ES2150378B1 (en) 1998-08-07 2001-07-01 Esteve Labor Dr EMPLOYMENT OF ARIL (OR HETEROARIL) AZOLILCARBINOLES DERIVATIVES IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISORDERS MEDIATED BY AN EXCESS OF SUBSTANCE P.
CA2246027A1 (en) 1998-08-27 2000-02-27 Virginia Commonwealth University Benzylamidine derivatives with serotonin receptor binding activity
PE20010781A1 (en) 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd COMPOUNDS 1- (1H-IMIDAZOL-4-IL) -1- (NAFTIL-2-SUBSTITUTED) ETHANOL, ITS PRODUCTION AND USE
JP2001302643A (en) 2000-04-21 2001-10-31 Suntory Ltd Cyclic amidine compound
EP1319070A2 (en) 2000-09-12 2003-06-18 Oregon Health &amp; Science University Mammalian receptor genes and uses
CA2427900A1 (en) 2000-11-14 2002-05-23 F. Hoffmann-La Roche Ag Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
TW200306783A (en) 2002-04-29 2003-12-01 Fmc Corp Pesticidal heterocycles
KR100492252B1 (en) 2002-08-09 2005-05-30 한국화학연구원 Benzopyran derivatives substituted with secondary amines including imidazole and their preparation
EP1449841A1 (en) * 2003-02-19 2004-08-25 Bayer CropScience SA New fungicidal compounds
WO2005033079A1 (en) * 2003-09-30 2005-04-14 Eisai Co., Ltd. Novel antifungal agent comprising heterocyclic compound
ATE537830T1 (en) * 2004-07-06 2012-01-15 Xenon Pharmaceuticals Inc NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTICS
US20060122236A1 (en) * 2004-12-06 2006-06-08 Wood Michael R Substituted biaryl-carboxylate derivatives
ES2329827T3 (en) * 2005-02-22 2009-12-01 F. Hoffmann-La Roche Ag NK1 ANTAGONISTS.
EP1869012A1 (en) 2005-04-05 2007-12-26 Boehringer Ingelheim International Gmbh Substituted benzylimidazoles useful for the treatment of inflammatory diseases
US20090209422A1 (en) 2005-05-03 2009-08-20 Bayer Cropscience Ag Insecticidal Substituted Aminoalkyl Heterocyclic and Heteroaryl Derivatives
WO2007024944A1 (en) 2005-08-25 2007-03-01 Schering Corporation Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
US20090005363A1 (en) * 2005-12-20 2009-01-01 Ralf Glatthar Organic Compounds
EP1987004A2 (en) * 2006-02-16 2008-11-05 Boehringer Ingelheim International GmbH Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents

Also Published As

Publication number Publication date
US8008305B2 (en) 2011-08-30
JP2010535209A (en) 2010-11-18
TW200914021A (en) 2009-04-01
EP2185502A1 (en) 2010-05-19
KR20100039438A (en) 2010-04-15
CN101784515A (en) 2010-07-21
AR067772A1 (en) 2009-10-21
BRPI0814758A2 (en) 2015-03-03
CA2695331A1 (en) 2009-02-12
AU2008285795A1 (en) 2009-02-12
KR101167773B1 (en) 2012-07-24
PE20090896A1 (en) 2009-07-15
CL2008002268A1 (en) 2009-05-29
US20090036452A1 (en) 2009-02-05
JP5341084B2 (en) 2013-11-13
WO2009019149A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
US8008305B2 (en) TAAR1 ligands
US20090036420A1 (en) Benzamide derivatives and their use for treating cns disorders
US9029370B2 (en) Substituted benzamide derivatives
AU2007312389B2 (en) Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors
AU2010335277A1 (en) Substituted benzamide derivatives
US9416127B2 (en) Triazole carboxamides and uses thereof
US9840501B2 (en) Morpholin-pyridine derivatives
US9487501B2 (en) Pyrazole carboxamide compounds and uses thereof
US9957261B2 (en) 6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives
US9663530B2 (en) 5-oxa-2-azabicyclo[2.2.2]OCTAN-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives
NZ616820B2 (en) Substituted benzamide derivatives

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION